These findings provided a comprehensive mutational characterization of AKT1, PIK3CA, PTEN and TP53 genes in Chinese breast cancer patients with valuable implications for clinical management and optimal design of clinical trials in the future. This evidence concerns the gene TP53 and breast cancer.